Read More In a $2B deal, Novo licenses obesity drug from Chinas United Bio Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co
If you see a piece of learning you would like to take, but havent got time right now, you can Bookmark it for later
Remission of type 2 diabetes mellitus (T2DM) after sleeve gastrectomy (SG), one-anastomosis gastric bypass (OAGB), and Roux-en-Y gastric bypass (RYGB): A systematic review
:
The Lancet+1 Pros of observational data: large numbers, real world
Entero-endocrine-osseous axis : gastrointestinal hormones as substrates for DPP-4 The initial observation that patients receiving long-term parenteral nutrition develop osteoporosis and osteomalacia raised suspicion about the lack of stimulation for the secretion of incretin hormones in this mode of nutrition and a potential connection between these hormones and bone metabolism [42]